- RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic…
Number of the records: 1  

RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?

  1. SYS0112942
    LBL
      
    00000naa--2200000-a-4500
    005
      
    20250607153932.1
    008
      
    150706c2015----xo-----e------------eng--
    040
      
    $a BA006 $b slo
    041
    0-
    $a eng $b eng
    044
      
    $a xo $c SK
    242
    10
    $a RAGE a jeho ligandy v nádore - vinníci, biomarkery alebo terapeutické ciele?: minireview $y slo
    245
    10
    $a RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets? : $b minireview / $c P. Tesarova ... [et al.]
    300
      
    $b ilustr., tab.
    504
      
    $a Bibliogr. odkazy
    504
      
    $a Res. angl.
    650
    12
    $7 sllk_us_auth*d009369 $a nádory $x etiológia $x metabolizmus $x terapia $2 mesh
    650
    12
    $7 sllk_us_auth*d017127 $a produkty pokročilej glykácie, konečné $x fyziológia $2 mesh
    650
    12
    $7 sllk_us_auth*d011971 $a receptory imunologické $x fyziológia $x genetika $x antagonisty a inhibítory $2 mesh
    650
    22
    $7 sllk_us_auth*d008024 $a ligandy $2 mesh
    650
    22
    $7 sllk_us_auth*d009418 $a S100 proteíny $2 mesh
    650
    22
    $7 sllk_us_auth*d015398 $a transdukcia signálna $2 mesh
    650
    22
    $7 sllk_us_auth*d017209 $a apoptóza $2 mesh
    650
    22
    $7 sllk_us_auth*d014408 $a biomarkery nádorové $2 mesh
    653
    2-
    $a receptor for advanced glycation end products (RAGE)
    653
    2-
    $a receptor pre koncové produkty pokročilej glykácie
    700
    1-
    $7 sllk_us_auth*0014718 $a Tesařová, Petra $u Onkologická klinika 1. LF UK a VFN v Praze $4 aut
    773
    0-
    $7 nnas $w sllk_us_cat*0111292 $t Neoplasma $f Cancer Research Institute of the Slovak Academy of Sciences $x 0028-2685 $d Bratislava : AEPress, 2015 $g Vol. 62, no. 3 (2015), s. 353-364
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.